PLCG2 and myelodysplastic syndrome: Remarkably, the presence of our inositide-mutated 3-gene cluster (PIK3CD, AKT3, and PLCG2) was significantly associated with a shorter OS, a shorter LFS and a shorter duration of response, possibly predicting the unfavorable effect of azacitidine and lenalidomide combination therapy in MDS patients.